PharmTech Drug Digest 11.20
News|Articles|September 5, 2014

Travtec Expands Operations in Lancashire

Travtec, a packaging line solutions specialist, has opened a second facility close to its Leigh, Lancashire headquarters. This move is part of an investment to expand the company?s operations to meet continuing demand for its systems, particularly as the pharmaceutical industry prepares for the current and forthcoming track and trace legislation, including the 2017 European Falsified Medicines Directive.

Travtec, a packaging line solutions specialist, has opened a second facility close to its Leigh, Lancashire headquarters. This move is part of an investment to expand the company’s operations to meet continuing demand for its systems, particularly as the pharmaceutical industry prepares for the current and forthcoming track and trace legislation, including the 2017 European Falsified Medicines Directive.

The new 150 m2 offices will house Travtec’s administrative support services, allowing its original building to increase its operational space by 200 m2. Travtec will be able to further expand its product offering, with the introduction of the full range of Lixis inspection equipment, including a blister vision system and pinhole detector.

Travtec specializes in the design and manufacture of product handling systems for a wide range of industries, including GSK, AstraZeneca, Merck, Bristol-Myers Squibb and Johnson & Johnson. The company’s product handling, coding and inspection systems are designed to complement inkjet printers, labellers, print and apply and thermal transfer equipment. Travtec works in partnership with OEMs to develop innovative new applications for both existing products and those under development. Travtec’s subsidiary company, Sunala, is the UK and Eire distributor for the Wolke m600 thermal inkjet printer for the pharmaceutical sector.

“This is an important milestone in the continuing growth of Travtec, enabling us to keep pace with customer demands throughout Europe,” commented Travtec managing director, Harry Thomason, in a press statement. “The new facilities and additional space will help to ensure we continue to devise and bring to market quickly innovative solutions that help our customers increase efficiencies.”

Source: Travtec


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.